iA Global Asset Management Inc. Takes Position in Labcorp Holdings Inc. $LH

iA Global Asset Management Inc. bought a new stake in Labcorp Holdings Inc. (NYSE:LH) during the fourth quarter, Holdings Channel reports. The institutional investor bought 7,609 shares of the medical research company’s stock, valued at approximately $1,909,000.

Other institutional investors have also modified their holdings of the company. JPL Wealth Management LLC acquired a new position in shares of Labcorp in the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Labcorp in the 4th quarter valued at $26,000. Eagle Bay Advisors LLC acquired a new position in shares of Labcorp in the 4th quarter valued at $29,000. Hantz Financial Services Inc. increased its holdings in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 40 shares during the period. Finally, Headlands Technologies LLC increased its holdings in shares of Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 96 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Labcorp

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the transaction, the executive vice president directly owned 2,579 shares in the company, valued at approximately $734,782.89. This represents a 17.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brian J. Caveney sold 1,500 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the completion of the transaction, the executive vice president owned 30,107 shares in the company, valued at approximately $8,619,935.17. This trade represents a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 16,656 shares of company stock worth $4,524,961. Corporate insiders own 0.84% of the company’s stock.

Labcorp Price Performance

NYSE:LH opened at $255.30 on Tuesday. The firm has a market cap of $20.93 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 1.75 and a beta of 0.91. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The company’s 50-day moving average is $264.92 and its two-hundred day moving average is $265.52. Labcorp Holdings Inc. has a 12-month low of $239.75 and a 12-month high of $293.72.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Research analysts expect that Labcorp Holdings Inc. will post 17.99 EPS for the current year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp’s dividend payout ratio is 25.51%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Robert W. Baird set a $334.00 price objective on shares of Labcorp in a research note on Friday, May 1st. JPMorgan Chase & Co. boosted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $308.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.